Clinical trial
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
NCT00165295 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165295 |
|---|---|
| Title | Sildenafil Citrate in Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Sildenafil citrate (Viagra) |
| Enrollment | 30 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | Jun 27, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: